New Millennium Group LLC Buys 1,562 Shares of Eli Lilly and Company (NYSE:LLY)

New Millennium Group LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1,131.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,700 shares of the company's stock after acquiring an additional 1,562 shares during the period. Eli Lilly and Company accounts for 0.9% of New Millennium Group LLC's portfolio, making the stock its 23rd largest holding. New Millennium Group LLC's holdings in Eli Lilly and Company were worth $1,404,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Citizens National Bank Trust Department lifted its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $43,000. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter worth about $48,000. Finally, Highline Wealth Partners LLC increased its stake in Eli Lilly and Company by 53.3% during the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock worth $57,000 after acquiring an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.4%

Shares of Eli Lilly and Company stock traded up $3.06 during trading on Wednesday, hitting $778.96. 1,977,577 shares of the stock traded hands, compared to its average volume of 3,674,984. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock's fifty day simple moving average is $778.38 and its 200 day simple moving average is $799.85. The firm has a market cap of $738.25 billion, a P/E ratio of 63.38, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the previous year, the company earned $2.58 earnings per share. The firm's revenue was up 45.2% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Analysts Set New Price Targets

Several research firms have recently issued reports on LLY. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Guggenheim reaffirmed a "buy" rating and set a $936.00 price objective on shares of Eli Lilly and Company in a research note on Friday, June 20th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.